FDA rejection

Wooden blocks with arrow and error icon Delays and disruptions stop the process critical error concept

Biotech

FDA rejects Aldeyra eye disease candidate for 3rd time

AbbVie has an option agreement for reproxalap, making Aldeyra eligible for a $100 million payment if the FDA approves the drug in dry eye disease.

Gabrielle Masson Mar 17, 2026 11:12am

stack of letters mail envelopes

FDA details Regenxbio rare disease rejection

Mar 3, 2026 12:56pm

big wave over ship in storm

Disc lays off 20% of workforce in wake of FDA rejection

Mar 3, 2026 10:45am

Image of a neon sign with the word no lit up next to an unlit yes

FDA rejects Regenxbio's Hunter syndrome gene therapy

Feb 9, 2026 4:05pm

Magnifying glass amplifying warning sign over falling stock figures

Corcept submitted lead asset for approval despite FDA warning

Jan 30, 2026 2:01pm

Union Square in San Francisco during JPM 2026

JPM26: Sanofi looks ahead to lingering US policy hurdles

Jan 14, 2026 2:28pm